Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; ISA 101 (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms OpcemISA
- Sponsors ISA Pharmaceuticals
- 16 Apr 2024 According to an ISA Pharmaceuticals media release, data from this trial will be presented at the at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual meeting.
- 28 Dec 2023 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 28 Dec 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.